Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer|Early-stage Breast Cancer|Breast Cancer|Breast Neoplasms|Stage II Breast Cancer|Stage IIIA Breast Cancer
Interventions: BIOLOGICAL: TX05 (trastuzumab)|BIOLOGICAL: Herceptin (trastuzumab)
Sponsor: Tanvex BioPharma USA, Inc.